Since the delisting of its Ordinary Shares on the London Stock Exchange plc's Main Market in September 2020, the Company has successfully delivered on its objective to develop and grow its business and, in so doing, has facilitated the delivery of high quality preventative pet healthcare by veterinary clinics to pet parents, across the UK, the USA and Europe. To enable PVG to capitalise on the significant market opportunity within its existing geographies and to accelerate Premier Veterinary Group plc's entry into new markets, the board of directors of PVG (the "Board") today announces that it is undertaking a formal review of the various strategic options available to the Company (the "Strategic Review"). The Strategic Review will examine all options, including, but not limited to, a possible offer for the entire issued and to be issued share capital of the Company.

The Company is subject to the City Code on Takeovers and Mergers (the "Code"). The Code has certain implications on some of the strategic options being considered. One of the options that will be considered in the Strategic Review is a potential sale of the Company by way of a "formal sale process" (as referred to in Note 2 on Rule 2.6 of the Code).

Commenting on the proposed Strategic Review, Dominic Tonner, CEO, said: "Veterinary groups are increasingly in the spotlight from regulators, the public and veterinarians with differing perceptions around the benefits of sector consolidation. As a result, veterinary groups are having to redouble efforts to further demonstrate the high quality of care to pets and service levels to pet parents actually enabled by corporate investment. At the same time, given the increasing cost of capital and greater regulatory scrutiny making M&A growth challenging, veterinary groups and independents are also looking at ways to drive better organic revenue growth to support their long-term investment plans.

Preventative pet healthcare plans have become a key pillar in organic growth strategies in recent years, providing benefits to veterinary clinics, pet parents and pets themselves. I believe as one of the world's leading end-to-end veterinary preventative health solutions providers with an industry leading proprietary technology platform, PVG is uniquely positioned to support its customers in the delivery of these strategies. This Strategic Review will explore how we can maximise long term value for our existing shareholders and help take PVG to the next level.

If the ultimate outcome results in a sale of the Company, I and the dedicated team of people at PVG look forward to welcoming a new partner who can support us both to accelerate our domestic and international growth, and to continue to invest in our proprietary platform and the development of our service offering." The Company has appointed Lincoln International LLP ("Lincoln") as its financial adviser for the Strategic Review and formal sale process and Rule 3 adviser under the Code.